S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:ATOS

Atossa Therapeutics - ATOS Stock Forecast, Price & News

$1.00
-0.01 (-0.99%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.99
▼
$1.02
50-Day Range
$0.91
▼
$1.28
52-Week Range
$0.84
▼
$4.31
Volume
726,837 shs
Average Volume
681,602 shs
Market Capitalization
$126.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Atossa Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
9.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.71 out of 5 stars

Medical Sector

1209th out of 1,283 stocks

Pharmaceutical Preparations Industry

577th out of 615 stocks

See Top Rated MarketRank™ Stocks Here
ATOS stock logo

About Atossa Therapeutics (NASDAQ:ATOS) Stock

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Therapeutics Stock Down 1.0 %

Shares of Atossa Therapeutics stock traded down $0.01 during trading on Friday, reaching $1.00. The company's stock had a trading volume of 726,837 shares, compared to its average volume of 681,602. Atossa Therapeutics has a 12-month low of $0.84 and a 12-month high of $4.31. The business has a 50 day moving average price of $1.04 and a 200-day moving average price of $1.14.

Atossa Therapeutics (NASDAQ:ATOS - Get Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.04) EPS for the quarter.

Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATOS Stock News Headlines

July 28, 2022 | seekingalpha.com
Atossa Therapeutics, Inc. (ATOS) Q2 2022 Results - Earnings Call Transcript
July 28, 2022 | finance.yahoo.com
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
August 7, 2022 | RJO Futures (Ad)
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
July 21, 2022 | americanbankingnews.com
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Significant Decline in Short Interest
July 11, 2022 | bizjournals.com
Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company
June 2, 2022 | finance.yahoo.com
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
May 18, 2022 | finance.yahoo.com
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
May 14, 2022 | finance.yahoo.com
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
August 7, 2022 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
April 27, 2022 | finance.yahoo.com
Atossa Therapeutics to Present at the Q2 Investor Summit Conference
April 20, 2022 | seekingalpha.com
Atossa rebounds after enrollment update on study for COVID-19 therapy
March 23, 2022 | finance.yahoo.com
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
March 8, 2022 | seekingalpha.com
Atossa Therapeutics issued patent covering breast cancer therapy endoxifen
March 1, 2022 | apnews.com
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
February 28, 2022 | finance.yahoo.com
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
February 8, 2022 | seekingalpha.com
IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losers
February 7, 2022 | finance.yahoo.com
The Olympics Business Model: Why Multi-Year Media Deals Matter
January 19, 2022 | marketwatch.com
Atossa Therapeutics Enrolling Patients in Part B Study for Covid-19 Treatment
January 18, 2022 | nasdaq.com
Atossa Therapeutics, Inc. Common Stock (ATOS)
January 18, 2022 | finance.yahoo.com
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
December 22, 2021 | finance.yahoo.com
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
December 16, 2021 | finance.yahoo.com
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur
December 6, 2021 | benzinga.com
Atossa Therapeutics Completes Pre-IND Meeting With FDA On Z-Endoxifen
December 6, 2021 | finance.yahoo.com
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
November 24, 2021 | finance.yahoo.com
Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”
November 15, 2021 | finance.yahoo.com
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
October 21, 2021 | finance.yahoo.com
Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
See More Headlines
Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATOS Company Calendar

Last Earnings
5/09/2022
Today
8/07/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATOS
CUSIP
N/A
CIK
1488039
Web
www.atossagenetics.com
Phone
(206) 588-0256
Fax
206-430-1288
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,610,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-15.71%
Return on Assets
-15.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
58.94
Quick Ratio
58.94

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.92

Miscellaneous

Outstanding Shares
126,620,000
Free Float
119,470,000
Market Cap
$126.62 million
Optionable
Not Optionable
Beta
1.65

Key Executives

  • Dr. Steven C. Quay FCAP (Age 71)
    M.D., Ph.D., Chairman, CEO & Pres
    Comp: $1.18M
  • Mr. Kyle Guse CPA (Age 58)
    Esq., CPA, CFO, Gen. Counsel & Sec.
    Comp: $693.62k
  • Ms. Heather Rees
    VP of Fin. & Accounting
  • Ms. Delly Behen P.H.R.
    VP of Admin. & HR
  • Mr. Charles Butler
    VP of Investor & PR
  • Ms. Janet Rose Rea MSPH
    RAC, Sr. VP of Regulatory, Quality & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATOS Stock - Frequently Asked Questions

How has Atossa Therapeutics' stock price performed in 2022?

Atossa Therapeutics' stock was trading at $1.60 at the beginning of the year. Since then, ATOS stock has decreased by 37.5% and is now trading at $1.00.
View the best growth stocks for 2022 here.

When is Atossa Therapeutics' next earnings date?

Atossa Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Atossa Therapeutics.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) issued its quarterly earnings results on Monday, May, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter.

When did Atossa Therapeutics' stock split? How did Atossa Therapeutics' stock split work?

Atossa Therapeutics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Therapeutics stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics CEO Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among Atossa Therapeutics' employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).

What is Atossa Therapeutics' stock symbol?

Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."

How do I buy shares of Atossa Therapeutics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atossa Therapeutics' stock price today?

One share of ATOS stock can currently be purchased for approximately $1.00.

How much money does Atossa Therapeutics make?

Atossa Therapeutics (NASDAQ:ATOS) has a market capitalization of $126.62 million. The company earns $-20,610,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does Atossa Therapeutics have?

Atossa Therapeutics employs 6 workers across the globe.

How can I contact Atossa Therapeutics?

Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The official website for Atossa Therapeutics is www.atossagenetics.com. The company can be reached via phone at (206) 588-0256, via email at scottg@coreir.com, or via fax at 206-430-1288.

This page (NASDAQ:ATOS) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.